Table 1.
Patient Characteristics for Eligible Patients
| Abiraterone Acetate (n=40) |
||
|---|---|---|
| AGE | ||
| Median, (range) | 66 (39, 85) | |
| TESTOSTERONE (ng/dl) | ||
| Median, (range) | 12.8 (3.0, 50.0) | |
| PSA AT ENTRY (ng/ml) | ||
| Median (Q1, Q3) ng/ml | 23.6 (11.7, 64.4) | |
| HISPANIC | ||
| Yes | 4 | 10% |
| No, unknown | 36 | 90% |
| RACE | ||
| White | 27 | 67% |
| Black | 10 | 25% |
| Asian | 2 | 5% |
| Native American | 1 | 2% |
| SWOG PS | ||
| 0–1 | 39 | 97% |
| 2 | 1 | 3% |
| GLEASON SCORE | ||
| 2–6 | 3 | 8% |
| 7 | 7 | 18% |
| 8–10 | 30 | 74% |
| METS TO BONE | 37 | 93% |
| LYMPH NODE METS | 8 | 20% |
| VISCERAL METS | 6 | 15% |
| PROSTATE RT | 5 | 13% |
| PROSTATECTOMY | 5 | 13% |
| ANTI-ANDROGEN USE | 35 | 88% |
| TIME FROM ANTI-ANDROGEN TO REG IN DAYS, MEDIAN (RANGE) | 74 (10, 371) | N=34 patients |
| PSA Status at Reg | N=40 patients | |
| Rising PSA | 34 | 85% |
| Stable/Falling PSA | 6 | 15% |
Abbreviations: Mets, Metastatic disease; PS, Performance status; PSA, Prostate specific antigen; REG, registration; RT, radiation therapy